You are here

Immune-based brain cancer diagnostic for rapid, accurate disease classification

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183360-01
Agency Tracking Number: R43CA183360
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
145 S 79TH ST, STE #9
CHANDLER, AZ 85226-4799
United States
DUNS: 78665294
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KATHRYN SYKES
 (480) 656-9360
 kathryn.sykes@healthtell.com
Business Contact
 KATHRYN SYKES
Phone: (480) 236-3875
Email: kathryn.sykes@healthtell.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Accurate, early disease diagnosis and monitoring are critical aspects to effective prevention, treatment, and remission of disease. Most diagnostic methods available today are not simple or sensitive enough to significantly impact patients' response to treatment or survival outcome. This unmet need is highlighted by diseases, such as brain cancers, that often remain asymptomatic at early stages and then grow aggressively- with fast, fatal outcomes. We have invented immunosignatures (IS) as a new approach to disease diagnoses that addresses these problems. IS is based on querying blood-serum. Using antibodies as biomarkers of disease takes advantage of a stable and easily accessible molecule and the immune system's convenient properties of diversity, surveillance, and biological amplification. The complexity of a mammalian immune system is staggering and therefore so is the information content. The reductions in cost, elimination of surgery, imaging, and the simplicit

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government